The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging.
| Inventor | Institute |
|---|---|
| Heather Mckinnon ; Justin Bower ; Daniel Croft | Cancer Research UK, Glasgow: The Beatson Institute |
| SKU: | 154151 |
|---|---|
| Product description: | This cell line has been engineered to enable tetracycline inducible expression of the kinase ROCK2. ROCK2 is a serine/threonine kinase which acts as a key regulator of the actin-myosin cytoskeleton and cell polarity. ROCK2 promotes contractile force generation and therefore is a modulator of cell motility and tumour cell invasion. The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when impla… |
| Alternate name: | Rho-associated protein kinase 2, Rho kinase 2, Rho-associated, coiled-coil-containing protein kinase 2, Rho-associated, coiled-coil-containing protein kinase II, ROCK-II, p164 ROCK-2 |
| Conditional: | Yes |
| Conditional description: | MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G regulated expression of ROCK2. Therefore ROCK2 expression is induced in the presence of doxycycline. |
| Additional notes: | Tet-On System owned by TET Systems GmbH & Co. KG. |
| Parental cell line: | MDA-MB-231 D3H2LN-Luc cell line |
| Disease: | Cancer |
| Cat. #: | 154151 |
|---|---|
| Provenance and Ownership: | The MDA-MB-231 TetOn-3G ROCK2 cell line is owned by Cancer Research UK. CancerTools supplies the MDA-MB-231 TetOn-3G ROCK2 cell line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing MDA-MB-231 TetOn-3G ROCK2 cell line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Organism: | Human |
| Tissue: | Breast |
| Model: | Transgenic |
| Growth properties: | Adherent cell line. Membrane blebbing/cytoskeleton reorganisation and migration induced in the presence of doxycycline. |
| Cancer Types In Detail: | Triple negative breast (TNBC) |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | 10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine |
| Recommended controls: | MDA-MB-231 D3H2LN-Luc parental line |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Unbekandt et al. 2014. Cell Commun Signal. 12:54. PMID: 25288205. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.